Cipher Pharmaceuticals Inc (CPHR) is Initiated by TD Securities to Buy

Cipher Pharmaceuticals Inc (CPHR) was Initiated by TD Securities to “Buy”. TD Securities advised their investors in a research report released on Apr 13, 2016.

Many Wall Street Analysts have commented on Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals Inc was Initiated by TD Securities to “Buy” on Apr 13, 2016.

Cipher Pharmaceuticals Inc opened for trading at $5.87 and hit $6.14 on the upside on Monday, eventually ending the session at $6.11, with a gain of 4.09% or 0.24 points. The heightened volatility saw the trading volume jump to 15,920 shares. Company has a market cap of $160 M.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. The Company acquires products that fulfill medical needs manages the required clinical development and regulatory approval process and markets those products either directly or through partners. The Company’s dermatology products include Sitavig Absorica Epuris Beteflam Dermadexin Pruridexin Ozenoxacin CF101 ASF-1096 and Nanolipolee-007. The Company’s other products include Lipofen Conzip and Durela.

Cipher Pharmaceuticals Inc

Leave a Reply

Cipher Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cipher Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.